<DOC>
	<DOCNO>NCT01153932</DOCNO>
	<brief_summary>The purpose study determine whether GSK2402968 give continuous dose intermittent dose effective safe treatment Duchenne muscular dystrophy .</brief_summary>
	<brief_title>Phase II Doubleblind Exploratory Study GSK2402968 Ambulant Subjects With Duchenne Muscular Dystrophy</brief_title>
	<detailed_description>This phase II , double-blind , exploratory , parallel-group , placebo-controlled clinical study ambulant subject DMD result mutation correct exon skipping induce GSK2402968 . The study aim randomise 54 subject . There 2 parallel cohort . Each cohort include subject GSK2402968 match placebo 2:1 ratio .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Ambulant subject Duchenne muscular dystrophy result mutation DMD gene , confirm stateoftheart DNA diagnostic technique cover DMD gene exon , include limited MLPA ( Multiplex Ligationdependent Probe Amplification ) , CGH ( Comparative Genomic Hybridisation ) HRMCA ( HighResolution Melting Curve Analysis ) , correctable GSK2402968induced DMD exon 51 skipping , Males , least 5 year age life expectancy least 1 year Able rise floor â‰¤7 second ( without aids/orthoses ) , Able complete 6MWD test distance least 75m Receiving glucocorticoid minimum 6 month immediately prior screening , significant change total daily dosage dose regimen minimum 3 month immediately prior screen reasonable expectation total daily dosage dose regimen change significantly duration study QTc &lt; 450msec On adequate contraception Able comply complete protocol requirement additional miss exon DMD Current history liver renal disease impairment Acute illness within 4 week first dose Use prohibit med within 6 month fist dose Current participation investigational clinical trial Positive hepatitis B surface antigen , hepatitis C antibody test , human immunodeficiency virus ( HIV ) test screen Symptomatic cardiomyopathy Children Care</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>968</keyword>
	<keyword>muscular dystrophy</keyword>
	<keyword>duchenne</keyword>
	<keyword>DMD</keyword>
</DOC>